Albireo Pharma Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Albireo Pharma stock.
View analyst ratings for Albireo Pharma or view top-rated stocks.

Wall Street analysts have given Albireo Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Albireo Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Albireo Pharma saw a decline in short interest in May. As of May 28th, there was short interest totaling 1,790,000 shares, a decline of 15.6% from the May 13th total of 2,120,000 shares. Based on an average daily volume of 161,600 shares, the short-interest ratio is currently 11.1 days. Approximately 9.5% of the company's stock are short sold.
View Albireo Pharma's Short Interest.

Albireo Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Albireo Pharma.

Albireo Pharma, Inc. (NASDAQ:ALBO) issued its quarterly earnings data on Wednesday, May, 5th. The biopharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.72) by $0.57. The biopharmaceutical company had revenue of $1.97 million for the quarter, compared to the consensus estimate of $2.65 million. Albireo Pharma had a negative net margin of 1,373.96% and a negative trailing twelve-month return on equity of 76.11%.
View Albireo Pharma's earnings history.

Albireo Pharma's stock was trading at $17.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALBO stock has increased by 100.5% and is now trading at $35.35.
View which stocks have been most impacted by COVID-19.

8 equities research analysts have issued 1 year price targets for Albireo Pharma's stock. Their forecasts range from $65.00 to $82.00. On average, they anticipate Albireo Pharma's share price to reach $72.00 in the next twelve months. This suggests a possible upside of 103.7% from the stock's current price.
View analysts' price targets for Albireo Pharma or view top-rated stocks among Wall Street analysts.

Some companies that are related to Albireo Pharma include IGM Biosciences (IGMS), Corcept Therapeutics (CORT), Axsome Therapeutics (AXSM), Prestige Consumer Healthcare (PBH), Amicus Therapeutics (FOLD), Pacira BioSciences (PCRX), MorphoSys (MOR), OPKO Health (OPK), FibroGen (FGEN), ALX Oncology (ALXO), Morphic (MORF), Global Blood Therapeutics (GBT), Prothena (PRTA), Revance Therapeutics (RVNC) and Centessa Pharmaceuticals (CNTA).
View all of ALBO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Albireo Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Federated Hermes Inc. (12.30%), BlackRock Inc. (6.66%), Chicago Capital LLC (3.59%), Dimensional Fund Advisors LP (1.84%), Geode Capital Management LLC (1.49%) and Goldman Sachs Group Inc. (1.17%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Jason Duncan, Life Sciences Maste Perceptive, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc and Simon NR Harford.
View institutional ownership trends for Albireo Pharma.

ALBO stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Federated Hermes Inc., Millennium Management LLC, Bank of Montreal Can, Northern Trust Corp, Ameriprise Financial Inc., Morgan Stanley, and Los Angeles Capital Management LLC. Company insiders that have sold Albireo Pharma company stock in the last year include Jan Mattsson, Jason Duncan, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, and Simon NR Harford.
View insider buying and selling activity for Albireo Pharma or view top insider-selling stocks.

ALBO stock was bought by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Dimensional Fund Advisors LP, Platinum Investment Management Ltd., Endurant Capital Management LP, Citigroup Inc., Rafferty Asset Management LLC, BlackRock Inc., and Geode Capital Management LLC. Company insiders that have bought Albireo Pharma stock in the last two years include Life Sciences Maste Perceptive, and Perceptive Advisors Llc.
View insider buying and selling activity for Albireo Pharma or or view top insider-buying stocks.

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALBO stock can currently be purchased for approximately $35.35.

Albireo Pharma has a market capitalization of $678.54 million and generates $8.31 million in revenue each year. The biopharmaceutical company earns $-107,630,000.00 in net income (profit) each year or ($6.73) on an earnings per share basis.

Albireo Pharma employs 90 workers across the globe.

Albireo Pharma was founded in 2003.

The official website for Albireo Pharma is www.albireopharma.com.

Albireo Pharma is headquartered at 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109.

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at (857) 254-5555 or via email at [email protected]